For Healthcare Professionals Outside the US

Improved adherence and satisfaction with EXJADE® (deferasirox)
film-coated tablets1,2

 
ADHERENCE TO THERAPY
DT, dispersible tablets; FCT, film-coated tablets.
aAt end of study (24 weeks). Consumed tablets was a patient-reported outcome.
 
Satisfaction With Therapy

At end of treatment, patients reported high satisfaction with exjade film-coated tablets1,2

DT, dispersible tablets; FCT, film-coated tablets.
aNote that these patient-reported outcomes (PROs) were secondary study end points assessed for both formulations using PRO questionnaires and diaries.
bBased on the 70% of patients who completed the PRO questionnaire at the end of the study.
 
Therapy Preference

EXJADE film-coated tablets is the formulation patients prefer2

DT, dispersible tablets; FCT, film-coated tablets.
Among evaluable patients at end of treatment.

Study design

About Iron Overload

References

Please note: In some countries, EXJADE film-coated tablets is available as JADENU® (deferasirox) tablets.